Tiziana Life Sciences
  • Our Company
    • Our Company
    • About us
    • Our Team
  • Technology
  • Pipeline
    • Intranasal Foralumab
      • Secondary Progressive Multiple Sclerosis
      • Alzheimer’s Disease
      • Other Indications
    • Anti IL-6R (TZLS-501)
    • Milciclib (TZLS-201)
  • Investors, News & Media
    • News
    • Media
    • Publications
    • Investors
  • Contact
Select Page
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

by Paul | 22 January 2025 | News

NEW YORK, January 22, 2025 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Recent Posts

  • Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
  • Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
  • Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
  • Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
  • Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

Recent Comments

No comments to show.

Tiziana Life Sciences, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda  |  info@tizianalifesciences.com   |  +44 (0) 207 495 2379

  • Follow
  • Follow

© Tiziana Life Sciences 2026  |   Legal  |  Privacy Policy

NASDAQ: TLSA